FINWIRES · TerminalLIVE
FINWIRES

$THC

14 stories mentioning THCUpdated 5d ago

Every FINWIRES story that references THC, newest first.

Wire

Tenet Healthcare Poised for Continued Earnings Growth Following Raised Outlook, Truist Says

Tenet Healthcare (THC) is positioned for continued earnings growth after strong Q2 results and raising its full year guidance, Truist said in a note Monday, citing momentum across its Hospital and Ambulatory businesses.The brokerage said "hospital trends were strong despite an expected payor mix headwind with solid volumes while ASC continues to roll along fueled by ongoing investment and core trends."Truist said cash flow generation remains attractive with full year guidance raised, providing incremental optionality around ongoing growth investment and shareholder value creation.The company reported Q2 revenue of $5.63 billion ahead of Truist estimate of $5.44 billion and consensus $5.43 billion. It also raised full year revenue outlook to between $21.90 billion and $22.50 billion from $21.50 billion to $22.30 billion and adjusted EPS to $20.30 to $21.69 from $16.38 to $18.68.Truist reiterated the company's buy rating and $270 price target.Price: $248.08, Change: $+14.88, Percent Change: +6.38%

$THC
Wire

Tenet Healthcare's Cost Discipline, Outpatient Growth Drive Strong Q2 Performance, RBC Says

Tenet Healthcare (THC) is demonstrating improved operational execution as cost discipline across its hospital and ambulatory segments, along with growth in its United Surgical Partners International platform, supported a strong Q2 performance and raised outlook, RBC Capital said in a Sunday note.According to the note, Tenet's adjusted earnings before interest, taxes, depreciation and amortization of $1.3 billion beat expectations, with revenue up 6.8% year over year to $5.6 billion, as margin expansion reflected cost management despite payer mix pressures, including lower exchange-related revenue.The brokerage highlighted Tenet's raised 2026 adjusted EBITDA guidance of $4.83 billion to $5.03 billion, with the midpoint up $295 million from prior guidance, reflecting core business outperformance and cost structure flexibility amid changing payer dynamics.The company's USPI platform is positioned to benefit from rising outpatient procedures, CMS inpatient-only list reforms and continued migration of procedures to ambulatory settings, supported by its acquisition pipeline, the report added.RBC maintained its outperform rating on the stock and raised its price target to $283 from $236.Tenet Healthcare shares were up over 5% in Monday trading.Price: $246.67, Change: $+13.47, Percent Change: +5.78%

$THC
Wire

UBS Adjusts Price Target on Tenet Healthcare to $308 From $288, Maintains Buy Rating

Tenet Healthcare (THC) has an average rating of buy and mean price target of $255, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $243.89, Change: $+10.69, Percent Change: +4.58%

$THC
Research

RBC Raises Price Target on Tenet Healthcare to $283 From $236, Keeps Outperform Rating

Tenet Healthcare (THC) has an average rating of buy and mean price target of $255, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$THC
Sectors

Sector Update: Healthcare Stocks Higher Late Afternoon

Healthcare stocks rose late Friday afternoon, with the NYSE Healthcare Index up 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.7%.The iShares Biotechnology ETF (IBB) decreased 0.3%.In corporate news, Tenet Healthcare (THC) shares surged past 17% after it posted higher Q2 adjusted earnings and revenue, and raised its 2026 guidance.Novo Nordisk (NVO) is seeking a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs, escalating the companies' legal dispute over weight-loss drug marketing, Reuters reported Friday. Novo shares rose 1.9%, and Lilly was up 0.6%.Profound Medical (PROF) said new data from a Level 1 evidence trial of its MRI-guided Tulsa procedure demonstrated statistically significant superiority over robotic radical prostatectomy in men with intermediate-risk prostate cancer. Its shares jumped past 8%.Lisata Therapeutics (LSTA) shares fell 16% after the company said it has terminated its planned merger with Kuva Labs.

$LLY$LSTA$NVO$PROF$THC
Wire

Tenet Healthcare Q2 Beats Expectations as Hospital, ASC Segments Outperform, UBS Says

Tenet Healthcare's (THC) Q2 results topped expectations, with both its hospital and ambulatory surgery center segments outperforming as lower-than-expected labor and operating costs drove an adjusted EBITDA beat, UBS Securities said.Results included an incremental benefit from supplemental payments, though the company did not specify how much of the $140 million increase in 2026 supplemental payment guidance was reflected in Q2 results versus the rest of the year, according to the note Thursday.The company raised its 2026 adjusted EBITDA guidance by $295 million at the midpoint, with $285 million of the raise in the hospital segment and a $10 million increase at its subsidiary, United Surgical Partners International. The guidance raise also included $140 million in incremental Medicaid supplemental payments, the note added.Tenet Healthcare is not seeing an increase in uninsured patients beyond what it expected from the exchanges, nor does it see any negative demand trends for surgical procedures, the brokerage said.UBS has a buy rating on Tenet with a price target of $288.Shares of Tenet Healthcare were up more than 16% in Friday trading.Price: $231.48, Change: $+32.46, Percent Change: +16.31%

$THC
Sectors

Sector Update: Healthcare Stocks Rise in Afternoon Trading

Healthcare stocks rose Friday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.8%.The iShares Biotechnology ETF (IBB) increased 0.2%.In corporate news, Novo Nordisk (NVO) is seeking a preliminary US court injunction to immediately block advertising by Eli Lilly (LLY) for its obesity and diabetes drugs, escalating the companies' legal dispute over weight-loss drug marketing, Reuters reported Friday. Novo shares rose 1.7%, and Lilly was up 1.3%.Tenet Healthcare (THC) shares jumped past 17% after it posted higher Q2 adjusted earnings and revenue, and raised its 2026 guidance.Scribe Therapeutics (SCTX) shares surged 50% in their Friday debut on Nasdaq after the company priced its IPO of 8.58 million shares at $15 per share.

$LLY$NVO$SCTX$THC
Sectors

Sector Update: Healthcare Stocks Flat to Higher Premarket Friday

Healthcare stocks were flat to higher premarket Friday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.3%.Tenet Healthcare (THC) shares were up more than 17% after the company posted higher Q2 adjusted earnings and revenue, and raised its 2026 guidance.MannKind's (MNKD) Furoscix ReadyFlow injection has been approved by the US Food and Drug Administration for the treatment of edema, or fluid overload, in adults with heart failure or chronic kidney disease, the company said. MannKind shares were up more than 2% pre-bell.Sanofi (SNY) stock was down more than 1% after the company said it stopped clinical testing and global regulatory applications for its amlitelimab medication for moderate-to-severe atopic dermatitis.

$IBB$MNKD$SNY$THC$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were flat to higher premarket Friday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.4%.Tenet Healthcare (THC) shares were up more than 17% after the company posted higher Q2 adjusted earnings and revenue, and raised its 2026 guidance.

$THC
Insider Trading

Tenet Healthcare Insider Sold Shares Worth $983,920, According to a Recent SEC Filing

J Robert Kerrey, Director, on May 28, 2026, sold 5,638 shares in Tenet Healthcare (THC) for $983,920. Following the Form 4 filing with the SEC, Kerrey has control over a total of 16,804 common shares of the company, with 16,804 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/70318/000119312526249167/xslF345X05/ownership.xml

$THC
Research

Research Alert: CFRA Maintains Buy Rating On Shares Of Tenet Healthcare

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month target price to $200 from $260, 11.4x our 2026 EPS estimate (up to $17.56 from $17.33; 2027 estimate up to $18.00 from $17.85), a discount to the company's three-year historical forward average of 12.9x. We think THC's valuation balances recent deleveraging efforts and a stronger margin profile than in previous years against policy headwinds, including cuts to Medicaid coverage under the OBBBA legislation and the recent expiration of ACA enhanced premium tax credits, which increases risk of higher uncompensated care. Same-facility ACA exchange admissions fell 10% Y/Y in Q1, and THC guides for a 20% reduction in ACA exchange patient volumes for 2026 and anticipates a negative $250 million impact on adjusted EBITDA. While we expect THC to revisit annual guidance in Q2 earnings, at which point a clearer picture of the insurance coverage landscape is likely, we look favorably on the company maintaining its annual inpatient/outpatient volume guidance for now.

$THC
Wire

RBC Cuts Price Target on Tenet Healthcare to $236 From $277, Keeps Outperform Rating

Tenet Healthcare (THC) has an average rating of buy and mean price target of $254.05 according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $184.94, Change: $+7.91, Percent Change: +4.47%

$THC
Research

Research Alert: Tenet Healthcare: Q1 Earnings Beat Despite Hospital Volume Headwinds

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Tenet Healthcare delivered Q1 adjusted EPS of $4.82 (+10.6% Y/Y), beating consensus by $0.65, while net operating revenues of $5.368B (+2.8% Y/Y) missed consensus by 0.5%. Consolidated adjusted EBITDA of $1.162B remained flat at 21.6% margins vs. the prior-year quarter. The Ambulatory Care segment supported the performance with revenues up 10.6% to $1.320B and adjusted EBITDA growing 6.1% to $484M, though margins compressed 150bps to 36.7%. The Hospital segment faced headwinds from ACA enhanced premium tax credit expiration, with revenues up only 0.5% to $4.048B and adjusted EBITDA declining 4.1% to $678M as margins compressed 80bps to 16.7%. The strong EPS beat and maintained margin guidance suggest confidence in underlying operational trends despite volume headwinds, in our view. THC maintained its FY 2026 adjusted EBITDA guidance of $4.485B-$4.785B while raising the adjusted EPS midpoint 1.2% to $17.53, supported by share repurchases.

$THC
Wire

Tenet Healthcare Shares Gain as Q1 Adjusted Earnings, Revenue Rise; 2026 EPS Guidance Raised

Tenet Healthcare (THC) shares were trading slightly higher Thursday as the company reported higher Q1 adjusted earnings and revenue.The company reported Q1 adjusted EPS of $4.82, up from $4.36 a year earlier. Analysts polled by FactSet expected $4.17.Net operating revenue for the quarter ended March 31 was $5.37 billion, up from $5.22 billion a year earlier.Analysts surveyed by FactSet expected $5.39 billion.For 2026, the company expects adjusted diluted earnings per share between $16.38 to $18.68, compared with $16.19 to $18.47 previously. Analysts expect $17.22.Full year revenue guidance was maintained at $21.50 billion to $22.30 billion. Analysts expect $22.01 billion.Price: $180.51, Change: $+0.31, Percent Change: +0.17%

$THC

Track with the FINWIRES app suite

FolioX
FolioX
Track THC in your portfolio
WheelAI
WheelAI
Analyze THC options with the wheel strategy
StockInsider
StockInsider
See market sentiment on THC